Open Philanthropy recommended an investment of $1,000,000 in Eradivir to support the development of an influenza antiviral drug. The team’s novel antiviral approach links two haptens that recruit the immune system to an already approved influenza antiviral, zanamivir, which binds to the neuraminidase protein found on the virus and infected cell.
This investment was funded via a request for proposals through the Pandemic Antiviral Discovery Initiative. It falls within our focus area of biosecurity and pandemic preparedness.